ENG and breast carcinoma: In line with these findings, compared to the conventional biomarker CD34, CD105 has been demonstrated to be a superior angiogenesis marker in breast cancer [3], malignant melanoma [4], non-small cell lung cancer [5], and colorectal carcinoma [6].